Analysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) Price Target at $68.06

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been given a consensus recommendation of “Moderate Buy” by the nineteen brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $68.0556.

A number of equities research analysts have weighed in on CRSP shares. UBS Group set a $80.00 target price on CRISPR Therapeutics in a research report on Friday, June 12th. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. Evercore restated an “outperform” rating and issued a $76.00 price objective on shares of CRISPR Therapeutics in a report on Monday, May 11th. Sanford C. Bernstein upped their price objective on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $55.00 target price on shares of CRISPR Therapeutics in a report on Thursday, August 6th.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $57.08 on Thursday. The stock’s fifty day moving average is $53.14 and its 200 day moving average is $52.43. CRISPR Therapeutics has a fifty-two week low of $44.12 and a fifty-two week high of $78.48. The firm has a market capitalization of $5.52 billion, a PE ratio of -11.99 and a beta of 1.74. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The firm had revenue of $10.18 million for the quarter. On average, sell-side analysts anticipate that CRISPR Therapeutics will post -4.47 earnings per share for the current year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the transaction, the insider directly owned 19,357 shares in the company, valued at approximately $1,076,636.34. The trade was a 16.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System boosted its position in CRISPR Therapeutics by 5,188.9% in the second quarter. California State Teachers Retirement System now owns 5,354,083 shares of the company’s stock valued at $292,012,000 after buying an additional 5,252,851 shares during the last quarter. Ameritas Advisory Services LLC acquired a new position in CRISPR Therapeutics in the 2nd quarter worth approximately $56,000. HB Wealth Management LLC purchased a new position in CRISPR Therapeutics during the 2nd quarter worth approximately $289,000. AlphaGrep UK Ltd purchased a new position in CRISPR Therapeutics during the 2nd quarter worth approximately $240,000. Finally, Shah Wealth Advisors LLC acquired a new stake in CRISPR Therapeutics during the 2nd quarter valued at approximately $3,767,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.